The use of fulvestrant, a pure Food and Drug Administration-approved ER antagonist devoid of agonist activities, is advantageous for hormone sensitive patients with advanced breast cancer, who have received high-dose chemotherapy [50]. Here, ESR1 is linked to breast carcinoma.